Nomura Holdings’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Nomura Holdings’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-14,000	Closed	-$66K	–	1779
2016 Q1	$66K	Buy	+14,000	New	+$55.9K	﹤0.01%	1431
2014 Q1	–	Sell	-10,820	Closed	-$140K	–	3014
2013 Q4	$140K	Sell	10,820 -5,428	-33%	-$64.8K	﹤0.01%	1801
2013 Q3	$164K	Buy	+16,248	New	+$145K	﹤0.01%	1965

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nomura Holdings's KERX Position: Q2 2016 in Review

Nomura Holdings sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2016, closing a stake of 14,000 shares — an estimated $66K sold.

Nomura Holdings first reported a position in KERX in Q3 2013 and held it in 3 quarters. The position peaked at $164K in Q3 2013. 118 funds tracked by Wall St. Rank hold KERX as of Q2 2016.

Nomura Holdings reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
Nomura Holdings sold 14,000 Keryx Biopharmaceuticals Inc shares in Q2 2016, an estimated $66K.
Nomura Holdings first reported a position in Keryx Biopharmaceuticals Inc in Q3 2013 and held it in 3 quarters.
Nomura Holdings's Keryx Biopharmaceuticals Inc position peaked at $164K in Q3 2013.
118 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2016.

Based on Nomura Holdings's 13F filing for Q2 2016, filed 15 Aug 2016.